Logo-bi
Bioimpacts. 2025;15: 30707 | Published on: 2025 Apr 06. doi: 10.34172/bi.30707

Original Article

Nanobody-functionalized liposomal doxorubicin: A novel strategy for angiogenesis suppression via VEGFR2 targeting

Aezam Akbari 1 ORCID, Azadeh Ghaffari 1, Fahimeh Haji-Ahmadi 2, Vahideh Farzam Rad 3, Mahdi Behdani 4, Hamidreza Kheiri-Manjili 1,5, Cobra Moradian 6, Davoud Ahmadvand 6 * ORCID

Cited by CrossRef:



As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMedPubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science IndicatorsEmbase; EBSCOhost; CAS: DOAJSHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons